Inside informationEnglish
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ose Immunotherapeutics
- Filed
- 15/04/2026, 07:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 115837_20260415